Gastrointestinal Cancer News

Incidence and prevalence of neuroendocrine tumors are steadily rising, possibly due to better detection of early-stage disease and stage migration, according to a retrospective, population-based study published in JAMA Oncology.

Luis A. Diaz, MD, has been named head of the division of solid tumor oncology in the department of medicine at Memorial Sloan Kettering Cancer Center.

Patients treated with PD-1/PD-L1 checkpoint inhibitors may be at an increased risk for adverse events after receiving the seasonal influenza vaccination, according to prospective study results presented at the European Lung Cancer Conference.

Researchers associated high-quality dietary patterns defined by four different diet quality indexes with a reduced risk for colorectal cancer across a number of racial and ethnic groups.

Gallbladder cancer rates have continued to decrease among men in recent years, but do not show the same trend among women, and the rate of late-stage diagnosis increased overall, according to new research published in Cancer Medicine.

Patients with a positive fecal immunochemical test who waited more than 10 months to undergo the required follow-up colonoscopy had a higher risk for colorectal cancer and a more advanced stage of disease at diagnosis compared with patients who underwent follow-up colonoscopy within a month, according to new research published in JAMA.

The FDA issued warning letters to 14 U.S. companies that the agency contends are selling products fraudulently claimed to prevent, diagnose, treat or cure cancer.

Tiziana announced approval in Israel of a phase 2 clinical trial to test the safety of milciclib, a novel inhibitor of cell cycle dependent kinases, in patients with refractory hepatocellular carcinoma, according to a press release.

The combination of abemaciclib plus an aromatase inhibitor significantly extended PFS among women with hormone receptor–positive, HER-2–negative advanced breast cancer, according to an interim analysis of a phase 3 study.

AMSTERDAM — Selective internal radiation therapy failed to best Nexavar in overall survival but did yield improvements in other parameters, including quality of life, in patients with hepatocellular carcinoma, according to data presented at the International Liver Congress.